Author:
Emri G, Orv Hetil 2001 Nov 25;142(47):2635-9 (Hungary)
|
[
Next Thread |
Previous Thread |
Next Message |
Previous Message
]
Date Posted: Wed, January 16 2002, 12:29:55 PST
In reply to:
Anna Lok, MD Thomas Shehab MD Mauricio Orrego, M.D. UMich
's message, "Doctors/Patients Not Following Through on Hepatitis C Screening" on Mon, July 30 2001, 8:16:52 PDT
Orv Hetil 2001 Nov 25;142(47):2635-9
[Article in Hungarian]
Emri G, Tornai I, Posan E, Sesztak T, Varga V, Horkay I.
Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos
Orvostudomanyi Kar, Borgyogyaszati Klinika.
The development of clinically overt porphyria cutanea tarda (PCT) can be
attributed to joint effects of genetic predisposition and environmental
factors. Regarding exogen factors, studies from several countries published
in the last years gave an account of significantly higher frequency of
chronic hepatitis C virus (HCV) infection in PCT patients compared to the
normal population. At the Department of Dermatology of University of
Debrecen the prevalence of positive anti-HCV antibodies has been found in
approximately 55% of PCT patients diagnosed from 1990 to 1999, which is
comparable to the average prevalence rate seen in Southern-European
countries. The majority of male patients were anti-HCV positive and
consumed regularly alcohol, whereas every female patient had taken
contraceptives. Liver enzymes were only slightly elevated in the majority
of the patients and liver biopsy had to be performed only in three patients
duo to chronic hepatitis. Our findings emphasise how important the
screening of PCT patients for anti-HCV antibody considering that it might
be important quo ad vitam for young men.
PMID: 11778362 [PubMed - in process]
[
Next Thread |
Previous Thread |
Next Message |
Previous Message
]
|
